X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
ICP-189 is a potent and selective oral allosteric inhibitor of SHP2, which is being evaluated in combiation with furmonertinib for the treatment of advanced or metastatic non-small cell lung cancer.
Lead Product(s): ICP-189,Furmonertinib
Therapeutic Area: Oncology Product Name: ICP-189
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2024
Details:
The net proceeds will be used to support company's activities for NDA approval process for furmonertinib, a novel, oral, highly brain-penetrant, EGFR kinase inhibitor designed for broad activity and selectivity across EGFR mutations.
Lead Product(s): Furmonertinib
Therapeutic Area: Oncology Product Name: AST2818
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Goldman Sachs & Co.
Deal Size: $175.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 25, 2024
Details:
The net proceeds will be used for the clinical development of (furmonertinib), which focuses on EGFR mutant-selective tyrosine kinase inhibitors (TKI) that are developed for the treatment of NSCLC patients.
Lead Product(s): Furmonertinib
Therapeutic Area: Oncology Product Name: AST2818
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Goldman Sachs & Co.
Deal Size: $135.7 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 22, 2024
Details:
AST2818 (furmonertinib) is an oral, small molecule, highly brain-penetrant, pan-EGFR mutant inhibitor that targets both classical (exon 19 deletion and L858R) and atypical EGFR mutations, including exon 20 insertion mutations as well as HER2 exon 20 insertion mutations.
Lead Product(s): Furmonertinib
Therapeutic Area: Oncology Product Name: AST2818
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 30, 2023
Details:
ICP-189 is a potent and selective oral allosteric inhibitor of SHP2, developed by InnoCare for the treatment of solid tumors as a single agent and/or in combination in combination with furmonertinib, a highly brain-penetrant, broadly active mutation-selective EGFR inhibitor.
Lead Product(s): ICP-189,Furmonertinib
Therapeutic Area: Oncology Product Name: ICP-189
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 13, 2023
Details:
Under the agreement, InnoCare and ArriVent will jointly evaluate the anti-tumor activity and safety of ICP-189, a novel SHP2 allosteric inhibitor, combined with furmonertinib, a highly brain-penetrant, broadly active mutation-selective EGFR inhibitor, in advanced NSCLC.
Lead Product(s): ICP-189,Furmonertinib
Therapeutic Area: Oncology Product Name: ICP-189
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Arrivent
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 13, 2023
Details:
The net proceedings will be used to support pivotal Phase 3 and additional studies with the Company’s lead product candidate AST2818 (furmonertinib), a highly brain penetrant, mutant-specific EGFR kinase inhibitor.
Lead Product(s): Furmonertinib
Therapeutic Area: Oncology Product Name: AST2818
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sofinnova
Deal Size: $155.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing March 27, 2023
Details:
The licensed small-molecule antagonist of EGFR ABK3376 is a pre-clinical candidate developed by Abbisko Therapeutics' proprietary drug discovery platform, which is a novel, highly potent, selective, and brain-penetrating new-generation EGFR inhibitor.
Lead Product(s): ABK3376,Furmonertinib
Therapeutic Area: Oncology Product Name: ABK3376
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Shanghai Allist Pharmaceuticals
Deal Size: $187.9 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 01, 2023
Details:
AST2818 (furmonertinib) is an oral, small molecule, highly brain-penetrant, pan-EGFR mutant inhibitor that targets both classical (exon 19 deletion and L858R) and atypical EGFR mutations, including exon 20 insertion mutations as well as HER2 exon 20 insertion mutations.
Lead Product(s): Furmonertinib
Therapeutic Area: Oncology Product Name: AST2818
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 05, 2022
Details:
Allist Pharma received approval for furmonertinib in EGFR T790M mutation-positive locally advanced or metastatic non-small-cell lung cancer (NSCLC) indications in China in March 2021.
Lead Product(s): Furmonertinib
Therapeutic Area: Oncology Product Name: AST2818
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hillhouse Capital Group
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing June 30, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
